• Explore /
  • Poster
  • / Outcomes of first-line (1L) ipilimumab and nivolumab (IPI-NIVO) and subsequent therapy in metastatic renal cell carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC).

Outcomes of first-line (1L) ipilimumab and nivolumab (IPI-NIVO) and subsequent therapy in metastatic renal cell carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC).

Abstract Poster

Authors

null

Chun Loo Gan

Tom Baker Cancer Center, University of Calgary, Calgary, AB, Canada

Chun Loo Gan , J Connor Wells , Andrew Lachlan Schmidt , Thomas Powles , Ben Tran , Luis A Meza , Chris Labaki , Jae-Lyun Lee , Lori Wood , Julia Shapiro , D. Scott Ernst , Anil Kapoor , Christina M. Canil , Takeshi Yuasa , Rana R. McKay , Benoit Beuselinck , Frede Donskov , Shaan Dudani , Toni K. Choueiri , Daniel Yick Chin Heng

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Genitourinary Cancer—Kidney and Bladder

Track

Genitourinary Cancer—Kidney and Bladder

Sub Track

Kidney Cancer

Citation

J Clin Oncol 39, 2021 (suppl 15; abstr 4554)

DOI

10.1200/JCO.2021.39.15_suppl.4554

Abstract #

4554

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

First Author: Audreylie Lemelin

First Author: Daniel M. Geynisman

First Author: Neil J. Shah

First Author: Pedro C. Barata